Caprolactam Chemicals Limited

Plant & Regd. Office:
Plot No. B-31, M.I.D.C. - Mahad,
Taluka - Mahad, Dist Raigad - 402 302.
Maharashtra, India • Tel. : (02145) 233427
CIN No. : L24110MH1988PLC049683
Web. : www.caprolactam.co.in
Email : caprolactamcl@gmail.com

13th November 2019

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai 400 001.
BSE Scrip Code: 507486

Dear Sir(s),

Sub.: Statement of Unaudited Standalone Financial Results for the quarter ended September 30th 2019.

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a Statement of Unaudited Standalone Financial Results for the quarter ended on 30th September 2019 along with Limited Review Report submitted by the Statutory Auditors of the Company.

The above financial results were approved by the Board of Directors at its meeting held on 13th November 2019. The meeting of the Board of Directors of the Company commenced at 12.00 p.m. and ended at 2.00 p.m.

Kindly take the same on your record.

We request you to inform your members accordingly.

Thanking you.

Yours faithfully,
For Caprolactam Chemicals Limited

Zaver Shankarlal Bhanushali
Managing Director
DIN: 00663374

Encl: As above

Caprolactam Chemicals Limited

CIN No. L24110MH1988PLC049683

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER ,2019

PART I							(Rs. In Lacs)
	PARTICULARS	Quarter Ended			6Months Ended		Year Ended
		(Unaudited)			(Unaudited)		(Audited)
		30-09-2019	30-06-2019	30-09-2018	30-09-2019	30-09-2018	31-03-2019
1	**Revenue From Operetion**						
	Revenue from Operations	117.523	237.282	54.150	354.805	113.973	518.841
	Other Income	0.141	0.318	0.206	0.459	0.273	7.208
	Total Income	**117.664**	**237.600**	**54.356**	**355.264**	**114.245**	**526.049**
2	**Expenses**						
(a)	Cost of materials consumed	-7.414	0.502	-38.326	-6.912	-15.318	26.324
(b)	Purchase of stock - I trade	0.000	0.000	0.000	0.000	0.000	0
(c)	Change in inventories of Finished goods, work-in-progress and stock-intrade	0.000	0.000	0.721	0.000	12.082	12.083
(C)	Employee benefits expenses	5.353	4.864	5.137	10.217	10.092	22.703
(d)	Finance Costs	6.749	8.099	9.955	14.848	15.285	34.128
(e)	Depreciation, depletion and amortisation expenses	28.090	27.340	26.434	55.430	44.429	96.840
(f)	**Other expenses**						
	(1) Other expenses	14.957	17.906	13.651	32.863	30.173	55.584
	(2) Utility	6.913	5.436	7.210	12.349	7.210	15.385
	(3) Electricity expenses	13.709	30.927	3.261	44.635	6.809	80.477
	(4) Labour	28.035	19.656	4.734	47.691	4.734	68.800
	(5) Repair	15.374	11.552	0.000	26.926	5.566	29.256
	(6) Spare Tools	7.705	7.154	40.711	14.859	46.477	20.050
	Total other expenses	**86.693**	**92.631**	**69.567**	**179.323**	**100.969**	**269.552**
	Total expenses	**119.471**	**133.436**	**73.488**	**252.906**	**167.539**	**461.630**
3	**Profit / (Loss) before exceptional items and tax**	**-1.807**	**104.164**	**-19.132**	**102.358**	**-53.294**	**64.419**
4	Exceptional items		0.000	0.000	0.000	0.000	0.000
5	**Profit before tax**	**-1.807**	**104.164**	**-19.132**	**102.358**	**-53.294**	**64.419**
6	**Tax expense**						
	Current tax	0.000	0.000	0.000	0.000	0.000	12.500
	Defered tax	0.000	0.000	0.000	0.000	0.000	1.755
	Total tax expenses	**0.000**	**0.000**	**0.000**	**0.000**	**0.000**	**14.255**
7	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	**0.000**	**0.000**	0.000	0.000	0.000	**0.000**
8	**Net Profit Loss for the period from continuing operations**	**-1.807**	**104.164**	**-19.132**	**102.358**	**-53.294**	**50.164**
9	Profit (loss) from discontinued operations before tax	0.000	0.000	0.000	0.000	0.000	0.000
10	Tax expense of discontinued operations	0.000	0.000	0.000	0.000	0.000	0.000
11	**Net profit (loss) from discontinued operation after tax**	**0.000**	**0.000**	**0.000**	**0.000**	**0.000**	**0.000**
12	Share of profit (loss) of associates and joint ventures accounted for using equity method	**0.000**	**0.000**	**0.000**	**0.000**	**0.000**	**0.000**
13	**Total profit (loss) for period**	**-1.807**	**104.164**	**-19.132**	**102.358**	**-53.294**	**50.164**
14	Other comprehensive income net of taxes	0.000	0.000	0.000	0.000	0.000	0.000
15	**Total Comprehensive Income for the period**	**-1.807**	**104.164**	**-19.132**	**102.358**	**-53.294**	**50.164**
16	**Total profit or loss, attributable to**	0.000	0.000	0.000	0.000	0.000	0.000

CAPROLACTAM CHEMICALS LIMITED

17	Profit or loss, attributable to owners of parent	0.000	0.000	0.000	0.000	0.000	0.000
18	Total profit or loss, attributable to non-controlling interests	0.000	0.000	0.000	0.000	0.000	0.000
19	**Total Comprehensive income for the period attributable to**	**0.000**	**0.000**	**0.000**	**0.000**	**0.000**	**0.000**
20	Comprehensive income for the period attributable to owners of parent	0.000	0.000	0.000	0.000	0.000	0.000
21	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0.000	0.000	0.000	0.000	0.000	0.000
22	**Details of equity share capital**						
	Paid-up equity share capital	**460.000**	**460.000**	**459.030**	**460.000**	**459.030**	**460.000**
	Face value of equity share capital	**10.000**	**10.000**	**10.000**	**10.000**	**10.000**	**10.000**
23	**Details of debt securities**						
24	**Reserves excluding revaluation reserve**						**-205.515**
25	**Earnings per share**						
26	**Earnings per equity share for continuing operations**						
	Basic earnings (loss) per share from continuing operations	**-0.039**	**2.264**	**-0.417**	**2.225**	**-1.161**	**1.091**
	Diluted earnings (loss) per share from continuing operations	**-0.039**	**2.264**	**-0.417**	**2.225**	**-1.161**	**1.091**
27	**Earnings per equity share for discontinued operations**						
	Basic earnings (loss) per share from discontinued operations	**0.000**	**0.000**	0.00	0.00	0.00	**0.000**
	Diluted earnings (loss) per share from discontinued operations	**0.000**	**0.000**	**0.000**	**0.000**	**0.000**	**0.000**
28	**Earnings per equity share**						
	Basic earnings (loss) per share from continuing and discontinued operations	**-0.039**	**2.264**	**-0.417**	**2.225**	**-1.161**	**1.091**
	Diluted earnings (loss) per share from continuing and discontinued operations	**-0.039**	**2.264**	**-0.417**	**2.225**	**-1.161**	**1.091**
29	Debt equity ratio						
30	Debt service coverage ratio						
31	Interest service coverage ratio						
27	**Disclosure of notes on finance results**						

1. The above results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13th November, 2019 and have been subjected to limited review by the Auditors.

2) The format of unaudited quarterly results as prescribed by SEBI's Circuler CIR/CFD/CMD/15/2015 dated 30th November2015 has been modified to comply wih the requirements of SEBI Circuler dated 5th July 2016, Ind AS and Schedule III to the Companies Act,2013.

3) As the Company's business activity falls within single significant business segment, viz." Manufacturing" no seprate segment information is enclosed.

4) There is no investors complain pending with the company.

5) Previous year figures have been regrouped wherever necessary.

Place: Mahad

Date: 13/11/2019

FOR AND BEHALF OF THE BOARD OF DIRECTORS

Mrs. Zaver S Bhanushali
Managing Director

CAPROLACTAM CHEMICALS LIMITED

(Amount in Rs. in lacs)

	Standalone Statement of Assets and Liabilities Particulars	Period ended As at 30-09-2019 Anaudited	Period ended As at 31-03-2019 Audited
	ASSETS		
1	**Non-current assets**		
	Property, plant and equiment	603.440	636.782
	Capital work-in-progress		
	Investment property		
	Goodwill		
	Other intangible assets		
	Intangible assets under development		
	Biological assets other than bearer plants		
	Investments accounted for using equity method		
	Non-current financial assets		
	Non-current investments		
	Tradereceivable, non-current		
	Loans, non-current		
	Other non-current financial assets		
	Total non-current financial assets		
	Deferred tax assets(net)		
	Other non-current assets		
	Total non-current assets	603.440	636.782
2	**Current assets**		
	Inventories	**16.123**	**9.211**
	Current financial assets		
	Current investments		
	Trade receivables	51.914	3.983
	Cash and cash equivalents	14.756	15.989
	Bank balance other than cash and cash equivalents	11.217	15.920
	loans, current		
	Other current financial assets	33.948	58.777
	Total Current financial assets	111.835	94.669
	Current tax assets (net)		
	Other current assets		
	Total current assets	**127.958**	**103.880**
3	**Non-current assets classified as held for sale**		
	Regulatory deferral account debit balances and related deferred tax assets		
	Total assets	**731.398**	**740.662**
	EQUITY AND LIABILITIES		
1	**Equity**		
	Equity attributable to owners of parent		
	Equity share capital	460.000	460
	Other equity	-103.158	-205.515
	Total equity attributable to owners of parent	356.842	254.485
	Non controlling interest		

CAPROLACTAM CHEMICALS LIMITED MAHAD

	Total equity	356.842	254.485
2	**Liablities**		
	Non-current liabilities		
	Non-current financial liabilities		
	Borrowings, non-current		
	Trade paybles, non-current		
	Other non-current financial liablities		
	Total non-current financial liablities		
	Provisions, non-current		
	Deferred tax liablities (net)	**24.307**	**24.307**
	Deferred government grants, Non -current		
	Total non-current liabilities	24.307	24.307
	Current liabilities		
	Current financial liabilities		
	Borrowings, current	230.645	327.645
	Trade paybles, current	64.710	80.527
	Other current financial liablities	54.284	41.198
	Total current financial liablities	349.639	449.370
	Other current liablities		
	Provisions, current	0.250	0.000
	Current tax liablities (net)	0.360	12.500
	Deferred government grants, current		
	Total current liablities	350.249	461.870
3	Liablities directly associated with assets in disposal group classified as held for sale		
	Regulatory deferral account credit balances and related deferred tax laiblity		
	TotaL liabilities	374.556	486.177
	Total equity and liablities	731.398	740.662
	Disclosure of notes on assets and liablities		
	1. The results of the quarter ended 30 September, 2019 were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13th November, 2019.		
	2. Previous Year Figures have been regrouped wherever necessary.		

Place: Mahad

Date: 13/11/2019

FOR CAROLACTAM CHEMICALS LIMITED

MANAGING DIRECTOR

CAPROLACTAM CHEMICALS LIMITED MAHAD

Bipin Kothari & Associates
CHARTERED ACCOUNTANTS

Bipin Kothari
B.Com, LL.B(Gen), F.C.A.

Limited Review Report

To
Board of Directors
Caprolactam Chemicals Limited

We have reviewed the accompanying statement of unaudited financial results of Caprolactam Chemicals Limited for the quarter and six month ended 30th September ,2019 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. The statement has been prepared by the pursuant to Regulation 33 of the SEBI (Listing Regulations and Disclosure Requirements)Regulation , 2015 (" the Listing Regulations , 2015) This statement is the responsibility of the Company's Management and has been approved by the Board of Directors at the meeting held on 13Th November 2019 . Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have performed an audit and accordingly, we express an unqualified audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of audited financial results prepared in accordance with applicable accounting standards Notified under companies Act 2013 (which are deemed to be applicable as per Section 133 of companies Act 2013, read with Rule 7 of the companies (accounts) Rules, 2014 and other recognized accounting practices and policies, generally accepted in India, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date : 13th November 2019
Place : Mumbai

For Bipin Kothari and Associates
Chartered Accountants

Proprietor

UDIN :- **19155037AAAADA2479**

+91 9870948284 +91 8355904949 / 022 25296138 cabipinkothari@gmail.com www.cabipinkothari.com

602, Pure Gold Premises, Opp. Saroj Sweets, Narayan Gajanan Marg, Nr. Chembur Rly Stn, Chembur East, Mumbai - 400 071.

CAPROLACTAM CHEMICALS LIMITED

CIN No. L24110MH1988PLC049683

CASH FLOW STATEMENT (Rs. In Lakhs)

	For the Hafl Year ended Septemer 30, 2019	For the Year Ended March 31, 2019
A. Cash Flow from Operating Activities		
Profit before Tax	**102.358**	**64.419**
Adjustments for :-		
Depreciation/Amortisation	55.430	**96.840**
Finance charges	14.848	**34.128**
Loss on obsolence/damage to assets	-	-
Operating Profit Before Working Capital Changes	**172.635**	**195.387**
Adjustments for changes in Working Capital		
(Increase)/Decrease in Sundry Debtors	(47.931)	**73.036**
(Increase)/Decrease in Inventories	(6.912)	**21.056**
(Increase)/Decrease in Loans and advances	24.829	**25.859**
Increase/(Decrease) in Current Liabilities	(14.622)	**(77.425)**
Cash Generated from Operations	**127.999**	**237.912**
Taxes paid (Including TDS)	-	12.500
Net Cash from Operating Activities - A	**127.999**	**225.412**
B. Cash Flow from Investing activities		
Purchase of Fixed Assets (Net)	(22.088)	(377.730)
Sale of Fixed Assets	-	-
Net Cash used in Investing activities - B	**(22.088)**	**(377.730)**
C. Cash Flow From Financing Activities		
Finance Charges	(14.848)	(34.128)
Increase in Capital	-	0.970
Increase in Short Term / Long Term Borrowings	(97.000)	138.263
Net Cash from Financing Activities - C	**(111.848)**	**105.104**
Net Increase/ Decrease (+/-) in Cash & Cash Equivalents	**(5.936)**	**(47.213)**
Cash and Cash Equivalents at the commencement of the	31.909	79.122
Cash and Cash Equivalents at the end of the year	25.973	31.909
	0	**0**

13-11-2019

Place :- Mahad

FOR AND BEHALF OF BOARD OF DIRECTORS

Mrs. Zaver S. Bhanushali

Managing Director